Tranexamic Acid for Severe Fistula Bleeding

Mechanism and Evidence

• Tranexamic acid (TXA) has demonstrated efficacy in various bleeding scenarios, including trauma-induced bleeding, with a favorable safety profile, as recommended by the European Heart Association 1, 2

Dosing and Administration

• For severe bleeding, the American College of Critical Care recommends administering 1g IV loading dose over 10 minutes, followed by 1g IV infusion over 8 hours, with early administration ideally within 3 hours of bleeding onset 1

Contraindications and Cautions

• The American College of Cardiology notes that TXA is contraindicated in disseminated intravascular coagulation (DIC) as it may worsen the condition, and should be used with caution in patients with history of thromboembolic disease or active thrombosis 3

Additional Management Considerations

• The European Heart Association recommends maintaining adequate diuresis, particularly important with TXA administration, and considering antifibrinolytics as part of a comprehensive approach to severe bleeding 2

Special Considerations

• The European Heart Rhythm Association guidelines support the use of TXA as an adjuvant therapy for bleeding management, and the British Society of Gastroenterology suggests that use of TXA in acute lower gastrointestinal bleeding should be confined to clinical trials, although this does not specifically address fistula bleeding 2, 4